News

American Association of Individual Investors15d
Why Perspective Therapeutics, Inc.’s (CATX) Stock Is Down 5.02%
Perspective Therapeutics, Inc.’s CATX share price has dipped by 5.02%, which has investors questioning if this is right time ...
Seeking Alpha2d
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Palatin successfully completed MELODY-1, its first Phase 3 study ... There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific ...
Medindia15d
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
"One of the important research questions that the study was designed to answer was whether a low- dose of an MC4R agonist could support long-term weight loss maintenance. We're excited with the ...
Seeking Alpha14d
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Consistent with known effects of GLP-1/GIP therapy ... There are five melanocortin receptors, MC1R through MC5R. Modulation of these receptors, through use of receptor-specific agonists, which ...
Hosted on MSN20d
Palatin’s UC therapy prompts clinical remission in a third of patients
A third of patients with active ulcerative colitis (UC) experienced clinical remission in a Phase II trial of Palatin Technologies’ melanocortin-1 receptor (MC1R) agonist, PL8177. The company ...
Rocky Mountain Collegian23d
The Rocky Mountain Collegian
The peptide is believed to interact with melanocortin-1 receptors (MC1R), which are primarily associated with the regulation of melanin synthesis. Research indicates that MC1R activation may lead ...